Product/Composition:- | Fosfomycin Oral Sachets or Powder for Suspension |
---|---|
Strength:- | 3g in a sachet |
Form:- | Oral Sachets or Powder for Suspension |
Reference Brands:- | Zyflo(US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Fosfomycin inhibits bacterial cell wall synthesis by targeting MurA, preventing peptidoglycan formation. Its oral sachets or powder for suspension offer broad-spectrum activity against resistant bacteria, especially in urinary tract infections. Benefits include effective, once-daily dosing, rapid bacterial eradication, minimal resistance development, and suitability for outpatient or pediatric use.
Fosfomycin oral sachets and powder for suspension are approved in the EU and US for uncomplicated urinary tract infections. In the EU, brands like Fosfomycin are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data; generics are available. Both regions require detailed dossiers including clinical trial results, quality documentation, and pharmacovigilance plans for approval and safety monitoring. For regulatory support, dossier preparation, and compliance, visit PharmaTradz. We facilitate seamless market access for fosfomycin oral formulations, ensuring adherence to European and US standards for safe and effective outpatient antimicrobial therapy.